It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
To adapt to changing hemodynamic demands, regulatory mechanisms modulate actin-myosin-kinetics by calcium-dependent and -independent mechanisms. We investigate the posttranslational modification of human essential myosin light chain (ELC) and identify NIMA-related kinase 9 (NEK9) to interact with ELC. NEK9 is highly expressed in the heart and the interaction with ELC is calcium-dependent. Silencing of NEK9 results in blunting of calcium-dependent ELC-phosphorylation. CRISPR/Cas9-mediated disruption of NEK9 leads to cardiomyopathy in zebrafish. Binding to ELC is mediated via the protein kinase domain of NEK9. A causal relationship between NEK9 activity and ELC-phosphorylation is demonstrated by genetic sensitizing in-vivo. Finally, we observe significantly upregulated ELC-phosphorylation in dilated cardiomyopathy patients and provide a unique map of human ELC-phosphorylation-sites. In summary, NEK9-mediated ELC-phosphorylation is a calcium-dependent regulatory system mediating cardiac contraction and inotropy.
Phosphorylation of the essential myosin light chain (ELC) influence actin-myosin crossbridge cycling in the heart. Here, the authors show upregulated ELC-phosphorylation in systolic heart failure and identify NIMArelated kinase 9 to bind to ELC mediating its calcium-dependent phosphorylation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details












1 University Hospital of Heidelberg, Kardiogenetikzentrum Heidelberg, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); Partner Site Heidelberg/Mannheim, DZHK (German Centre for Cardiovascular Research), Berlin, Germany (GRID:grid.452396.f) (ISNI:0000 0004 5937 5237); University Hospital of the Ruhr-Universität Bochum, Clinic for General and Interventional Cardiology/ Angiology, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany (GRID:grid.418457.b) (ISNI:0000 0001 0723 8327)
2 University Hospital of Heidelberg, Kardiogenetikzentrum Heidelberg, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); Partner Site Heidelberg/Mannheim, DZHK (German Centre for Cardiovascular Research), Berlin, Germany (GRID:grid.452396.f) (ISNI:0000 0004 5937 5237)
3 University of Leipzig, Clinic and Polyclinic for Cardiology, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786)
4 Partner Site Heidelberg/Mannheim, DZHK (German Centre for Cardiovascular Research), Berlin, Germany (GRID:grid.452396.f) (ISNI:0000 0004 5937 5237); University of Heidelberg, Department of Medicine III, Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373)
5 Heidelberg University, CFMP, Core Facility for Mass Spectrometry & Proteomics at ZMBH, Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373); Heidelberg University, ZMBH, Center for Molecular Biology, Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373)
6 University of Heidelberg, Department of Medicine III, Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373)
7 Saarland University, Clinical Bioinformatics, Saarbrücken, Germany (GRID:grid.11749.3a) (ISNI:0000 0001 2167 7588); Stanford University Medical School, Department of Neurology and Neurological Sciences, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
8 University Hospital of the Ruhr-Universität Bochum, Clinic for General and Interventional Cardiology/ Angiology, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany (GRID:grid.418457.b) (ISNI:0000 0001 0723 8327)
9 Heidelberg University, ZMBH, Center for Molecular Biology, Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373)
10 Partner Site Heidelberg/Mannheim, DZHK (German Centre for Cardiovascular Research), Berlin, Germany (GRID:grid.452396.f) (ISNI:0000 0004 5937 5237); Stanford University Medical School, Stanford Genome Technology Center, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
11 University Hospital of Heidelberg, Kardiogenetikzentrum Heidelberg, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); Partner Site Heidelberg/Mannheim, DZHK (German Centre for Cardiovascular Research), Berlin, Germany (GRID:grid.452396.f) (ISNI:0000 0004 5937 5237); Stanford University Medical School, Stanford Genome Technology Center, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)